Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT01060514
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pazopanib — DRUG
    dose escalation, administered orally, daily
  • Vinorelbine — DRUG
    dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)

Study Details

The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects. Also, this study will evaluate what effects (good and bad) that the treatment has on patients and their cancer.

Key Dates

Start date
Feb 28, 2010
Status verified
Oct 2013
Primary completion
Feb 29, 2012
Completion
Sep 30, 2013

Study Design

Enrollment
8 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pazopanib + Vinorelbine

Primary Outcome Measure

To determine the maximum tolerated dose (MTD), and the recommended Phase II dose to be used in patients with metastatic NSCLC and breast cancer. [ Time Frame: at study completion (estimated at 2 years) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern University, Northwestern Medical Faculty FoundationChicagoIllinois60611-

Find similar trials in Chicago, IL

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Northwestern University, Northwestern Medical Faculty Foundation· Chicago, IL

Related Studies